Why is "SeaGen" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-04-01 14:36:35
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
This topic is not currently in the ranking.
Wikipedia Overview
SeaGen was the world's first large scale commercial tidal stream generator. It was four times more powerful than any other tidal stream generator in the world at the time of installation in 2008. It was decommissioned by SIMEC Atlantis Energy Limited in summer 2019, having exported 11.6 GWh to the grid since 2008.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Pfizer adds to Seagen scrap heap with another early cancer candidate cull - Fierce Biotech
-
Pfizer Reshapes Portfolio With Seagen And Metsera As COVID Winds Shift - Yahoo Finance
-
Pfizer Earnings: Seagen Impairment and Metsera Tolerability Data Incrementally Negative - Morningstar Canada
-
Daiichi Sankyo prevails on appeal in long-running ADC patent battle with Seagen, flipping prior $41.8M verdict - Fierce Pharma
-
CAFC Kills Cancer Treatment Patent Claims Due to Lack of Written Description, Enablement - IPWatchdog.com
-
Pfizer’s modest 2026 outlook shows its big investments will take time to pay off - CNBC
-
Pfizer's Seagen bet gets a lift as Tukysa delivers front-line win in breast cancer - FirstWord Pharma
-
Daiichi wins appeal of $42 million US verdict in Enhertu patent case - Reuters
-
One of Adcetris’s twin sons strikes out | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
-
The Federal Circuit Raises the Section 112 Stakes for Chemical Structures in Seagen v. Daiichi - JD Supra
-
Fed. Circ. Erases $41.8M Verdict Over Seagen Cancer Drug IP - Law360
-
Pfizer Cuts 100 From Former Seagen HQ Amid ‘Digital Enablement and Automation’ Push - BioSpace
-
Pharma giant Pfizer to acquire Seagen for $43 billion - People Matters SEA
-
Pfizer to Lay Off 100 Employees from Former Seagen HQ Amid Cost Cuttings - Pharmaceutical Executive
-
Pfizer's parade of pipeline cuts: Seagen, BioNTech and MASH programs among 11 axed - Fierce Biotech
-
Pfizer scores again in HER2-positive breast cancer, this time with Seagen's Tukysa - Fierce Pharma
-
Daiichi escapes Enhertu royalties as appeals court tosses Seagen ADC patent claims - FirstWord Pharma
-
Pfizer downgrades disitamab again | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
-
Pfizer lays off 100 workers at former Seagen HQ in Seattle area - Fierce Pharma
-
Pfizer lays off 100 employees in Seattle area - GeekWire
-
Pfizer CEO Reportedly Drops F-Bomb On Live TV Discussing Seagen, Metsera Deals - Stocktwits
-
Pfizer cuts office space at former Seagen headquarters in Bothell - The Business Journals
-
Seagen’s $42 Million Chemotherapy Patent Win Nixed on Appeal (2) - Bloomberg Law News
-
Jim Cramer on Pfizer: “We are Still on the Verge of Finding Out What the Seagen Acquisition Does” - Yahoo Finance
-
Pfizer lays off 100 workers at former Seagen headquarters in Bothell - The Business Journals
-
Federal Circuit Court of Appeals Vacates Infringement Judgment and Damages Award in Dispute between Daiichi Sankyo and Seagen - Business Wire
-
Pharma company lays off 100 in Seattle area - The Seattle Times
-
Pfizer lays off 100 employees in Bothell, cites growth in automation, efficiency - MyNorthwest.com
-
Pfizer - Fierce Pharma
-
Pfizer starts its PD-L1 conjugate with lung first | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
-
Like MacroGenics, Sanofi tries to square an uneasy circle | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
-
SABCS25: Pfizer's Tukysa cuts risk of progression by 36% in HER2+ breast cancer - FirstWord Pharma
-
Daiichi Sankyo avoids payout in long-running patent dispute with Pfizer’s Seagen - Endpoints News
-
Roger Dansey, M.D., ex-Pfizer and Seagen, joins Nurix (NASDAQ: NRIX) board of directors - Stock Titan
-
Pfizer looks past COVID with $43 bln deal for cancer drug maker Seagen - Reuters
-
The Truth About Seagen Inc (Acquired): Why Wall Street Moved On But The Story Isn’t Over - AD HOC NEWS
-
Pfizer to raise $31 billion in debt offering to fund Seagen acquisition, SEC filing shows - CNBC
-
One cancer drug steps back, and obesity asset steps forward, as Pfizer reports earnings - Endpoints News
-
Pfizer: Competitive Advantages Still Exist, but Signs of Erosion Lead Us to Lower Our Valuation - Morningstar Canada
-
Pfizer Agrees to Buy Seagen for $43 Billion - WSJ
-
Seagen Is Gone From Nasdaq—Why the Pfizer Deal Still Matters to You - AD HOC NEWS
-
Pfizer’s $43B Seagen acquisition doubles early-stage oncology clinical pipeline - Labiotech.eu
-
Pfizer gets OK for $43-billion Seagen deal after donating cancer drug rights - Reuters
-
Seagen’s Vanishing Ticker: What Happens To A Biotech Star After A $43 Billion Takeover? - AD HOC NEWS
-
Pfizer to buy Seagen in $43B cancer drug deal - BioPharma Dive
-
RemeGen's latest bladder cancer success for ADC bodes well for Pfizer - FirstWord Pharma
-
Pfizer abandons $350m+ Seattle plant post-Seagen acquisition - BioProcess International
-
Pfizer doubles down on PD-L1 conjugates | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
-
Pfizer stops buildout of $350M Seagen plant, leaving 120 workers' roles in question - Fierce Pharma
-
FTC asks Pfizer, Seagen for more information on proposed $43B merger - Fierce Pharma
-
With $43B buyout, Pfizer sees cancer specialist Seagen as a 'goose' laying 'golden eggs' - Fierce Pharma
-
Pfizer shuffles its deck post-Seagen | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
-
Done deal: Pfizer completes $43B acquisition of Seagen, doubling its oncology pipeline - Fierce Pharma
-
Exclusive | Pfizer in Talks to Acquire Seagen in Deal Likely Valued at More Than $30 Billion - WSJ
-
In Pfizer's $43B acquisition of Seagen, the biotech's patience paid off - Fierce Pharma
-
Seagen’s Biologics Manufacturing Facility, Everett, Washington - Pharmaceutical Technology
-
Exclusive | Merck Is in Advanced Talks to Buy Seagen for Roughly $40 Billion or More - WSJ
-
Pfizer Inc. (PFE) Acquires Seagen for $43 Billion, Strengthening Oncology Leadership - Yahoo Finance
-
Pfizer buys Bothell-based Seagen for $43B, boosts access to cancer drugs - The Seattle Times
-
Pfizer Completes Acquisition of Seagen - Business Wire
-
After Pfizer deal, former Seagen CEO returns to lead oncology startup - BioPharma Dive
-
Pfizer in talks to buy cancer drugmaker Seagen - WSJ - Reuters
-
Pfizer Completes 43 Billion Acquisition of Seagen - FTI Consulting
-
Pfizer is betting on next-gen cancer drugs to offset slowing demand for COVID vaccines - qz.com
-
In a year of turnover, Seagen doled out $126M to a trio of CEOs - Fierce Pharma
-
Novartis, Seagen veteran David Epstein is back, leading a new cancer startup - statnews.com
-
Seagen Reports Fourth Quarter and Full Year 2022 Financial Results - Business Wire
-
Seagen, Merck put $1.6B ADC collab on the back burner citing 'emerging treatment landscape' - Fierce Biotech
-
Pfizer axes B7-H4 ADC, triggering $1B impairment charge as blockbuster vision evaporates - Fierce Biotech
-
Seagen Third Quarter 2023 Financial Results Reflect Strong Product Sales Growth, and Significant Portfolio and Pipeline Progress - Business Wire
-
Pfizer to close Seagen manufacturing plant in Seattle area following $43B acquisition - GeekWire
-
Pfizer buys Seagen for $43B, boosts access to cancer drugs - AP News
-
Pfizer looks beyond Covid sales with $43 billion deal for cancer drugmaker Seagen - CNBC
-
Seagen's breast cancer therapy succeeds in late-stage study - Reuters
-
Did Seagen Acquisition Help Pfizer Inc. (PFE) Increase Revenue in Q1? - Yahoo Finance
-
Spotlight On: Bourla defends cost of Seagen deal as Pfizer looks to long-game in ADCs - FirstWord Pharma
-
Pfizer CEO says it will be able to deliver Seagen's cancer therapy at a scale not seen before with $43 billion deal - CNBC
-
Pfizer favored over Merck for Seagen acquisition: SVB analyst - Yahoo Finance
-
Seagen’s cancer drug succeeds in ‘must-win’ trial - BioPharma Dive
-
Pfizer Clears Final Regulatory Hurdles to Acquire Seagen Inc. - Pharmaceutical Executive
-
Former Seagen CEO unveils new startup Ottimo Pharma - Fierce Biotech
-
Seagen, amid deal rumors, spends $50M on a dual-targeting cancer drug - BioPharma Dive
-
Green light for Seagen's pivotal integrin beta-6 trial | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
-
Without Pfizer appeal, Daiichi Sankyo closes long-running ADC patent arbitration with $47M win - Fierce Pharma
-
Seattle Genetics shortens name to Seagen, dropping local connection as it goes global - Fierce Pharma
-
Pfizer shuffles R&D leadership to prepare for Seagen merger - Fierce Biotech
-
Pfizer (PFE) to Purchase Cancer Drugmaker Seagen (SGEN) for $43 Billion - Bloomberg.com
-
Merck-Seagen deal unlikely to happen before companies report quarterly earnings: WSJ - Fierce Pharma
-
Merck in talks to buy cancer biotech Seagen: report - Fox Business
-
ADC startup ProfoundBio, led by Seagen veterans, raises $112M - BioPharma Dive
-
Pfizer finds room for ADC snack after swallowing Seagen, inking deal for mesothelin candidate - Fierce Biotech
-
Are DACs the new ADCs? Seagen pays Nurix $60M to find out - Fierce Biotech
-
Pfizer Wins Seagen Sweepstakes with $43B Bid - BioSpace
-
Pfizer will acquire Seattle-area biotech giant Seagen for $43 billion - GeekWire
-
Pfizer Inks Potential $1B ADC Deal with Nona, Closes Seagen Acquisition - BioSpace
-
JPM24: Even after Seagen buyout, Pfizer oncology chief still eyes ADC deals - Fierce Pharma
-
Pfizer wins regulatory approval for its $43B acquisition of Seattle-area biotech giant Seagen - GeekWire
-
Seagen’s Cancer Therapy Is Making It a Takeover Target - WSJ
-
Seagen Strikes $2.6 Billion ADC Deal with China’s RemeGen - BioSpace
-
Pfizer to buy Seagen for $43B - BioWorld News
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.